Brendan J Guercio1, Sui Zhang2, Fang-Shu Ou3, Alan P Venook4, Donna Niedzwiecki5, Heinz-Josef Lenz6, Federico Innocenti7, Bert H O'Neil8, James E Shaw9, Blase N Polite10, Howard S Hochster11, James N Atkins12, Richard M Goldberg13, Kaori Sato2, Kimmie Ng2, Erin Van Blarigan4, Robert J Mayer2, Charles D Blanke14,15, Eileen M O'Reilly16, Charles S Fuchs17, Jeffrey A Meyerhardt2. 1. Brigham and Women's Hospital, Boston, MA. 2. Dana-Farber/Partners CancerCare, Boston, MA. 3. Mayo Clinic, Rochester, MN. 4. University of California, San Francisco, San Francisco, CA. 5. Duke University, Durham, NC. 6. University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA. 7. University of North Carolina at Chapel Hill, Chapel Hill, NC. 8. Indiana University School of Medicine, Indianapolis, IN. 9. Medstar Washington Hospital Center, Washington, DC. 10. University of Chicago, Chicago, IL. 11. Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ. 12. Southeast Clinical Oncology Research Consortium, National Cancer Institute Community Oncology Research Program, Winston-Salem, NC. 13. West Virginia University Cancer Institute, Morgantown, WV. 14. SWOG, Portland, OR. 15. Oregon Health & Science University, Portland, OR. 16. Memorial Sloan Kettering Cancer Center, New York, NY. 17. Yale School of Medicine, New Haven, CT.
Abstract
PURPOSE: Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored. PATIENTS AND METHODS: We conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850), a National Cancer Institute-sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss. RESULTS: The final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend = .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend = .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend < .001). CONCLUSION: Among patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events.
PURPOSE: Regular physical activity is associated with reduced risk of recurrence and mortality in patients with nonmetastatic colorectal cancer. Its influence on patients with advanced/metastatic colorectal cancer (mCRC) has been largely unexplored. PATIENTS AND METHODS: We conducted a prospective cohort study nested in Cancer and Leukemia Group B (Alliance)/SWOG 80405 (ClinicalTrials.gov identifier: NCT00265850), a National Cancer Institute-sponsored phase III trial of systemic therapy for mCRC. Within 1 month after therapy initiation, patients were invited to complete a validated questionnaire that reported average physical activity over the previous 2 months. On the basis of responses, we calculated metabolic equivalent task (MET) hours per week to quantify physical activity. The primary end point of the clinical trial and this companion study was overall survival (OS). Secondary end points included progression-free survival (PFS) and first grade 3 or greater treatment-related adverse events. To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within 60 days of activity assessment and used Cox proportional hazards regression analysis to adjust for known prognostic factors, comorbidities, and weight loss. RESULTS: The final cohort included 1,218 patients. Compared with patients engaged in less than 3 MET hours per week of physical activity, patients engaged in 18 or more MET hours per week experienced an adjusted hazard ratio for OS of 0.85 (95% CI, 0.71 to 1.02; PTrend = .06) and for PFS of 0.83 (95% CI, 0.70 to 0.99; PTrend = .01). Compared with patients engaging in less than 9 MET hours per week, patients engaging in 9 or more MET hours per week experienced an adjusted hazard ratio for grade 3 or greater treatment-related adverse events of 0.73 (95% CI, 0.62 to 0.86; PTrend < .001). CONCLUSION: Among patients with mCRC in Cancer and Leukemia Group B (Alliance)/SWOG 80405, association of physical activity with OS was not statistically significant. Greater physical activity was associated with longer PFS and lower adjusted risk for first grade 3 or greater treatment-related adverse events.
Authors: Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Briant Fruth; Jeffrey A Meyerhardt; Deborah Schrag; Claire Greene; Bert H O'Neil; James Norman Atkins; Scott Berry; Blase N Polite; Eileen M O'Reilly; Richard M Goldberg; Howard S Hochster; Richard L Schilsky; Monica M Bertagnolli; Anthony B El-Khoueiry; Peter Watson; Al B Benson; Daniel L Mulkerin; Robert J Mayer; Charles Blanke Journal: JAMA Date: 2017-06-20 Impact factor: 56.272
Authors: Jeffrey A Meyerhardt; Edward L Giovannucci; Michelle D Holmes; Andrew T Chan; Jennifer A Chan; Graham A Colditz; Charles S Fuchs Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: Jeffrey A Meyerhardt; Denise Heseltine; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; James Thomas; Heidi Nelson; Renaud Whittom; Alexander Hantel; Richard L Schilsky; Charles S Fuchs Journal: J Clin Oncol Date: 2006-07-05 Impact factor: 44.544
Authors: B E Ainsworth; W L Haskell; A S Leon; D R Jacobs; H J Montoye; J F Sallis; R S Paffenbarger Journal: Med Sci Sports Exerc Date: 1993-01 Impact factor: 5.411
Authors: Barbara J Nicklas; Fang-Chi Hsu; Tina J Brinkley; Timothy Church; Bret H Goodpaster; Stephen B Kritchevsky; Marco Pahor Journal: J Am Geriatr Soc Date: 2008-11 Impact factor: 5.562
Authors: A M Wolf; D J Hunter; G A Colditz; J E Manson; M J Stampfer; K A Corsano; B Rosner; A Kriska; W C Willett Journal: Int J Epidemiol Date: 1994-10 Impact factor: 7.196
Authors: Mark Hamer; Severine Sabia; G David Batty; Martin J Shipley; Adam G Tabák; Archana Singh-Manoux; Mika Kivimaki Journal: Circulation Date: 2012-08-13 Impact factor: 29.690
Authors: Kyoung-A Kim; Sang Hui Chu; Eui Geum Oh; Sang Joon Shin; Justin Y Jeon; Yun Jin Lee Journal: Support Care Cancer Date: 2020-08-06 Impact factor: 3.603
Authors: William H Ward; Caitlin R Meeker; Elizabeth Handorf; Maureen V Hill; Margret Einarson; R Katherine Alpaugh; Thomas L Holden; Igor Astsaturov; Crystal S Denlinger; Michael J Hall; Sanjay S Reddy; Elin R Sigurdson; Efrat Dotan; Matthew Zibelman; Joshua E Meyer; Jeffrey M Farma; Namrata Vijayvergia Journal: JCO Clin Cancer Inform Date: 2021-01
Authors: Brendan J Guercio; Sui Zhang; Fang-Shu Ou; Alan P Venook; Donna Niedzwiecki; Heinz-Josef Lenz; Federico Innocenti; Michael N Pollak; Andrew B Nixon; Brian C Mullen; Bert H O'Neil; James E Shaw; Blase N Polite; Al Bowen Benson; James N Atkins; Richard M Goldberg; Justin C Brown; Eileen M O'Reilly; Robert J Mayer; Charles D Blanke; Charles S Fuchs; Jeffrey A Meyerhardt Journal: JNCI Cancer Spectr Date: 2020-08-27
Authors: Andrew E Hendifar; Maria Q B Petzel; Teresa A Zimmers; Crystal S Denlinger; Lynn M Matrisian; Vincent J Picozzi; Lola Rahib Journal: Oncologist Date: 2018-12-27 Impact factor: 5.837
Authors: Erin L Van Blarigan; Sui Zhang; Fang-Shu Ou; Alan Venlo; Kimmie Ng; Chloe Atreya; Katherine Van Loon; Donna Niedzwiecki; Edward Giovannucci; Eric G Wolfe; Heinz-Josef Lenz; Federico Innocenti; Bert H O'Neil; James E Shaw; Blase N Polite; Howard S Hochster; James N Atkins; Richard M Goldberg; Robert J Mayer; Charles D Blanke; Eileen M O'Reilly; Charles S Fuchs; Jeffrey A Meyerhardt Journal: JAMA Netw Open Date: 2020-10-01